## **Core Concept**
HER2/neu, also known as ERBB2, is a gene that can play a role in the development of breast cancer. Overexpression of the HER2/neu protein occurs in approximately 20% of breast cancers and is associated with more aggressive tumor behavior and a worse prognosis. The HER2/neu protein is a member of the epidermal growth factor receptor family and promotes the growth of cancer cells.

## **Why the Correct Answer is Right**
The correct answer, , states that HER2/neu overexpression is associated with a worse prognosis but also that patients with HER2/neu-positive tumors benefit from targeted therapies such as trastuzumab, pertuzumab, and ado-trastuzumab emtansine. These drugs specifically target the HER2/neu protein, leading to improved outcomes for patients with HER2/neu-positive breast cancer.

## **Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because it does not accurately reflect the relationship between HER2/neu overexpression and breast cancer prognosis or treatment.
* **Option B:** This option is incorrect because it suggests that HER2/neu overexpression is associated with a better prognosis, which is not accurate.
* **Option C:** Although not provided, any statement contradicting established facts about HER2/neu overexpression in breast cancer would be incorrect.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that HER2/neu status is routinely tested in breast cancer patients because it guides treatment decisions, particularly regarding the use of targeted therapies. Patients with HER2/neu-positive tumors are candidates for HER2-targeted therapy, which has significantly improved outcomes for this subgroup.

## **Correct Answer:** . Overexpression of HER2/neu in breast cancer is associated with aggressive disease but also with responsiveness to targeted therapy.